Kornimate/medical-research-clean huggingface dataset:
study of a bupivacaine patch (eladur™) to treat post- herpetic neuralgia

Conditions: Postherpetic Neuralgia; Pain

Summary: neuropathic pain is caused by a virus commonly associated with chicken pox. this virus may become dormant in the nervous system and later reactivate causing herpes zoster, also known as "shingles". post-herpetic neuralgia (phn) is a persistent pain in the area of healed skin lesions. this study will test the safety and efficacy of treating phn patients with the analgesic patch, bupivacaine tts (eladur™).


Eligibility criteria:
inclusion criteria: * male or females age 21 years or older. * pain in thoracic or lumbar regions for a minimum of 90 days after crusting of herpes zoster (hz) lesions. * stable prescribed medications regimen (including opioids, anticonvulsants, and tricyclic antidepressants). * intact, unbroken skin over the painful area to be treated. * body mass index (bmi) no more than 35 kg/m2. exclusion criteria: * active hz lesions, dermatitis, central nervous system (cns) injury. * any immunosuppressed condition, including but not limited to aids/hiv and hodgkin's lymphoma. * pain control by nerve block or neurosurgical intervention. * evidence of clinically significant hepatic, gastrointestinal, renal, hematologic, urologic, neurologic, respiratory, endocrine or cardiovascular system abnormalities, psychiatric disorders, or acute infection. * connective tissue disorders (systemic lupus erythematosus, scleroderma, mixed connective tissue disease). * recent use (within 30 days preceding the first treatment visit) of any topically applied pain medication, such as nonsteroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics (including lidoderm®), steroids or capsaicin products on the painful areas. * significant pain of an etiology other than phn, for example, compression-related neuropathies (e.g., spinal stenosis), fibromyalgia or arthritis. patients must not have significant ongoing pain from other cause(s) that may interfere with judging phn related pain. * participation in a clinical trial of an investigational product or device within 30 days of the screening visit or concurrently during the conduct of this study.

Keywords: herpes zoster shingles phn post herpetic neuralgia neuropathic pain
can amino acid supplementation augment the anabolic response in tendon after exercise

Conditions: Tendinopathy

Summary: the goal of this study is to determine if an oral provision of amino acids will enhance exercise-induced increases in markers of achilles tendon collagen production.

tendon pain is a common complaint in older adults. the mechanisms contributing to the large number of tendon problems in older adults are not known. it has been shown that tendon cross-sectional area (csa) is reduced with aging concurrent with a significant loss of tendon collagen. exercise is used to reverse the loss of muscle mass with aging but surprisingly exercise interventions designed to reduce tendon problems in older people are relatively unexplored. in young adults, exercise stimulates tendon collagen synthesis and enhances the production of growth factors, which stimulate tendon collagen production. it is presumed that exercise-induced increase in collagen synthesis contributes to the increase in tendon stiffness and csa noted in young adults after chronic resistance exercise (re). in contrast, our preliminary work indicates that re is not effective at reducing the effects of aging on tendon. the investigators have demonstrated that 12-weeks of re does not lead to increases in tendon csa or stiffness, even when skeletal muscle mass and strength are greatly enhanced. to prevent tendon injury, greater tendon csa and stiffness aid in withstanding the force generated by trained skeletal muscle. greater csa and stiffness also optimize force transfer through tendon to maximize musculoskeletal function. our findings indicate that re is not an optimal intervention for reversing age-related changes in tendon properties. novel interventions are clearly needed that will enhance collagen synthesis leading to an increase in tendon stiffness and csa while also improving skeletal muscle mass and strength in older individuals. this study will evaluate the effectiveness of various methods for stimulating tendon collagen synthesis during a bout of acute exercise. specifically, the investigators propose two approaches to this problem. 1. an acute bout of cycling exercise will enhance the release of growth factors leading to a larger increase in tendon collagen synthesis. 2. a bolus of amino acids given orally will increase the release of key stimulators of tendon collagen synthesis leading to enhanced collagen synthesis after acute exercise.

Eligibility criteria:
inclusion criteria: * 21-35 years or 60-80 years old exclusion criteria: * diabetes * bmi\>35 * acute illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, metabolic disorders, arthritis, or a history of neuromuscular problems. * chronic pain medication users * alcoholism * competitive athletes * pregnant women will be excluded * individuals with specific allergies to amino acids

Keywords: tendon amino acid exercise
a clinical evaluation of the treatment of spider veins on the ankles

Conditions: Spider Veins

Summary: to evaluate the safety and effectiveness of the excel v system for the treatment of lower extremity spider veins on the ankles.

the purpose of this study is to evaluate the real-world effectiveness of the 532 nm and 1064 nm nd:yag lasers within the cutera excel v system for the treatment of lower extremity spider veins, specifically on the ankles, within a clinic setting.

Eligibility criteria:
inclusion criteria: 1. males or females, 20 to 75 years of age (inclusive). 2. fitzpatrick skin type i - iii. 3. having spider veins on at least 1 ankle measuring 2.0mm or less in diameter, linear or branching, and red, pink, blue and/or purple in color, as assessed by the investigator. 4. having spider veins on the ankle that are appropriate for laser treatment, as assessed by the investigator. 5. subject must be able to read, understand and sign the informed consent form. 6. subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions. 7. wiling to have limited sun exposure for the duration of the study, including the follow-up period. 8. willingness to have digital photographs taken of ankle spider veins and agree to use of photographs for presentation, educational or marketing purposes. 9. agree not to undergo any other procedure for the treatment of ankle spider veins during the study. exclusion criteria: 1. fitzpatrick skin type iv - vi. 2. pregnant. 3. having an infection, dermatitis or a rash in the treatment area. 4. having significant varicosities or perforator veins. 5. history of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. 6. systemic use of isotretinoin (accutane®) within 6 months of study participation. 7. excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. 8. in the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systemic therapy that could interfere with this research study.
alzheimer's disease: potential benefit of isoflavones

Conditions: Alzheimer's Disease

Summary: the purpose of this pilot study is to evaluate the potential effects of soy isoflavone supplements on cognitive function for men and women with alzheimer's disease (ad). preliminary studies evaluating the effects of soy supplements on memory in cognitively healthy older adults have yielded promising results that are now being evaluated in patients with ad. it is hypothesized that isoflavone supplements will ameliorate cognitive declines for older adults diagnosed with alzheimer's disease, when compared to subjects on placebo.


Eligibility criteria:
inclusion criteria: * diagnosis of probable ad * has reliable and available caregiver to assist with medication and appointments * on a stable dose of cholinesterase inhibitor, or if unable to tolerate medication, patient has no plans to re-initiate cholinergic therapies while in the study exclusion criteria: * current or recent use (\<6 months) of menopausal hormone replacement therapy (hrt) * current or recent use (\<4 months) or oral antibiotic therapy * typical dietary intake of soy isoflavones \>5 mg/day * history or significant gastro-intestinal or colon disease, or colon/intestinal resection * irritable bowel syndrome * history of breast cancer, or abnormal mammogram within 12 months * history of chronic obstructive pulmonary disease, diabetes mellitus, liver disease or unstable ischemic heart disease * significant neurological disease other than ad that might affect cognitive function, such as stroke, parkinson's disease, multiple sclerosis, or serious traumatic brain injury
genome sequencing in refractory breast cancer to molecular targeted therapy and young breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.

the hypothesis is that genomic profiling measured by cancerscan, cfdna, whole exome sequencing (wes), whole transcriptome sequencing (wts), facs(fluorescence-activated cell sorting), cytokine and immunologic signature analysis would be helpful to find out tolerance for chemotherapy and innovate new therapeutic strategies.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed breast cancer that is either metastatic or young breast cancer(≤ 40 years of age). 2. her2 positive patient who failed her2 target therapy including trastuzumab with feasible biopsy site. 3. triple negative breast cancer patient who failed standard therapy with feasible biopsy site. 4. hormone receptor positive patient who failed standard therapy with feasible biopsy site. 5. age ≥ 21 years 6. written informed consent exclusion criteria: 1. no feasible biopsy site 2. no written informed consent
optic nerve sheath ultrasound during electroconvulsive therapy

Conditions: Intracranial Pressure Change; Hypertension; Electroconvulsive Therapy Treated Patients

Summary: electroconvulsive therapy (ect) is an effective method that has been used for many years in the treatment of psychiatric disorders and is currently administered under general anesthesia. this study evaluated the effect of ect on intracranial pressure by measuring the optic nerve sheath diameter (onsd) using ultrasonography. the primary aim was to determine how onsd values measured during the postictal period change compared to baseline values. secondary objectives included identifying factors related to the participants and the ect procedure that affect onsd.

electroconvulsive therapy (ect) is a treatment method that has been used effectively for many years in the treatment of psychiatric disorders. typical uses of ect include depression, schizophrenia, bipolar disorder, cases resistant to standard therapies, individuals at risk of suicide, and patients exhibiting symptoms of catatonia. the safety of ect remains a highly debated issue. it is commonly believed that ect should be avoided in cases of tumors or other space-occupying lesions due to concerns that the therapys stimulus or induced seizure could lead to increased intracranial pressure. the american psychiatric association task force report recommends a detailed evaluation of the risk-benefit ratio and measures to minimize the risks associated with the treatment. measurement of the optic nerve sheath diameter (onsd) with ultrasound is a direct, noninvasive, and rapid technique for assessing raised icp. comparisons between ocular sonography and magnetic resonance imaging (mri) have shown an acceptable correlation and reliability. in this study, the effects of ect on intracranial pressure were evaluated by measuring the optic nerve sheath diameter (onsd) using ultrasonography. the primary aim was to determine the change in onsd value during the postictal period compared to baseline. secondary objectives include identifying participants and ect procedure-related factors affecting onsd.

Eligibility criteria:
inclusion criteria: * 18 years and older * asa 1,2,3 * participants with various psychiatric problems requiring ect exclusion criteria: * intracranial mass, edema, or bleeding observed on mri scan * previous eye surgery * severe cataracts * glaucoma * optic atrophy * other severe sight impairment * traumatic brain injury, space-occupying, and inflammatory lesions

Keywords: intracranial pressure change hypertension electroconvulsive therapy
study to assess the effect of bms-791325 on the pharmacokinetics of midazolam in healthy subjects

Conditions: Hepatitis C

Summary: the purpose of this study is to assess the effect of bms-791325 on the pharmacokinetics of the cyp3a4 probe midazolam.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects aged 18 to 49 years, with bmi of 18-32 kg/m² * women who are not of childbearing potential exclusion criteria: * women of childbearing potential * women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable method of birth control. * gastrointestinal disease that may impact the absorption of study drug * history of any chronic respiratory disease (asthma, copd)

Keywords: human volunteers
survey of inpatients on integrative therapy methods

Conditions: Patient Satisfaction and Experience With Integrative Therapies

Summary: observational study of general patient satisfaction and inpatients' experiences with integrative therapies. the study recruits inpatients of the filderklinik, an anthroposophic hospital in southwestern germany. the aim is to assess overall patient satisfaction and inpatients' experiences with integrative therapies at the filderklinik.

this is a cross-sectional study to investigate general patient satisfaction and inpatients' experiences with integrative therapies in an anthroposophic hospital. participants will be recruited at the filderklinik, a hospital in southwestern germany that uses anthroposophic medicine (am) on a broad basis. inpatients who have received at least 10 treatments with one or more of the different integrative therapy methods will be asked for their willingness to participate. after providing written informed consent, participants will complete a questionnaire on integrative therapies received and overall patient satisfaction. in addition, data from the clinic database will be analyzed and cross-checked with the questionnaire data to verify and specify information about the participating sample. the focus of the study is to assess general patient satisfaction and experience with integrative therapy methods among inpatients at the filderklinik.

Eligibility criteria:
inclusion criteria: * written informed consent * filderklinik inpatient who had at least 10 treatments with one ore more of the integrative therapy methods * age 18 years or older exclusion criteria: * insufficient german language skills * legally incapacitated patients * patients who are physically incapable of giving written consent * patients in isolation wards

Keywords: integrative therapies anthroposophic medicine overall patient satisfaction inpatients survey
effectiveness of a personalized in-home telerehabilitation program on self-care in patients with long covid

Conditions: Long COVID Syndrome

Summary: the goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme with monitoring via a mobile app produces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent covid. the main questions it aims to answer are: * will a multimodal program (exercise with education) improve the self-management ability of patients with post-exertional malaise? * does fatigue and quality of life will be improved in these patients? researchers will compare an experimental breath program to a control standard care group to see if multimodal program works to treat post-exertion malaise. participants will: * follow-up 12 weeks online sessions: 1 weekly synchronous online session + 1 scheduled asynchronous session + educational resources * daily use of the app: daily log, education and questions


Eligibility criteria:
inclusion criteria: * post covid-19 condition: individuals with a history of probable or confirmed sars-cov-2 infection, usually 3 months from the onset of covid-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. common symptoms include fatigue, shortness of breath, cognitive dysfunction * between 18 and 75 years of age * possibility of access and use of smartphone. * ability to attend the clinic in person for an initial session. exclusion criteria: * patients with a history of respiratory or cardiovascular diseases prior to covid-19, other acute or chronic diseases that may interfere with the study * pregnancy/breastfeeding * those with contraindications to respiratory muscle training.

Keywords: post-acute covid-19 syndrome self-management covid-19 rehabilitation exercise
the effect and safety of hemodialysis and hemoperfusion on severe renal osteopathy and itching in uremia patients

Conditions: Hyperparathyroidism; Refractory Pruritus; Ostalgia; Insomnia

Summary: a prospective, randomized, controlled open clinic trial to evaluate the effect and safety of combination of conventional hemodialysis(hd) and hemoperfusion(hp) on middle molecules removal and complications improvement in long-term maintenance hemodialysis (mhd) patients. there are two phases of study for each subject. phase 1 (screening phase). during this phase, each potential subject will be evaluated to determine if he/she is eligible for the study. phase 2 (intervention phase). each subject will be randomly allocated to hd+hp(ha130 once per week) group ,hd+hp(ha330 once per week) group and hd group. the follow-up duration was 3 months.

all patients recruited from these centers who met the inclusion criteria were randomly allocated to hd+hp(ha130 once per week) group ,hd+hp(ha330 once per week) group and hd group. the follow-up duration was 3 months. hemoperfusion is performed by ha130 or ha330 resin adsorbents. blood flow is 200ml/min，dialysate flow is 500ml/min， hemodialysis and hemoperfusion last for 2.5h，continue hd after removing the adsorbent to complete 4 hours'treatment.heparin for anticoagulation ：first pulse 0.5-1mg/kg ，appending 8-10mg/h. primary endpoint is the improvement of the clinic symptoms, meanwhile secondary endpoint is serum β2mg、ipth、crp、adma、bmp2 decrease compared with the baseline, life quality, nutrition condition, and cardiovascular (cvd) incidence.

Eligibility criteria:
inclusion criteria: * willingness to sign an informed consent * stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session * middle or large molecules retention defined as immunoreactive parathyroid hormone (ipth) \> 400 pg/ml, β2mg\>5000 pg/ml、crp\>10mg/l. * refractory pruritus, carpal tunnel syndrome, restless leg syndrome, hyperparathyroidism or other refratory complications. exclusion criteria: * incapable or reluctant to sign the informed consent or comply the schedule. * platelet (plt) count\<60×109/l or disturbance in coagulation, tendency of severe bleeding or acute bleeding. * severe hypotension and heart or lung insufficiency * known hypersensitive or contradiction or intolerance to dialyzer or adsorbents * attend to other clinic trial now or in recent 30 days

Keywords: hemodialysis hyperparathyroidism refractory pruritus ostalgia insomnia cvd incidence life quality
thiotepa-based conditioning for allogeneic stem-cell transplantation (sct) in lymphoid malignancies

Conditions: Non Hodgkin Lymphoma; Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Multiple Myeloma

Summary: the study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.


Eligibility criteria:
inclusion criteria: 1. age less than physiologic 68 years. 2. patients with mm, nhl, hl and cll with an indication for allogeneic transplantation as follows: 1. mm; patients relapsing after autologous transplant or with high-risk cytogenetic abnormalities 2. aggressive lymphoma and hodgkin lymphoma; relapse after autologous transplants 3. follicular lymphoma; failure of at least one prior regimen 4. cll; failure of prior therapy which includes fludarabine combinations or 17p- cytogenetic abnormality 3. patients must have an hla matched related or unrelated donor willing to donate either peripheral blood stem cells or bone marrow. matching is based on high-resolution class i (hla-a, -b, -c) and class ii (hla-drb1, -dqb) typing. the goal is to transplant \> 3 x 106 cd34+ cells per kg body weight of the recipient 4. patients must sign written informed consent. 5. adequate birth control in fertile patients. exclusion criteria: 1. bilirubin \> 3.0 mg/dl, transaminases \> 3 times upper normal limit 2. creatinine \> 2.0 mg/dl 3. ecog-performance status \> 2 4. uncontrolled infection 5. pregnancy or lactation 6. abnormal lung diffusion capacity (dlco \< 40% predicted) 7. severe cardiovascular disease 8. cns disease involvement 9. pleural effusion or ascites \> 1 liter 10. known hypersensitivity to fludarabine or treosulfan 11. psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate
evaluation of the effectiveness of the training given to mothers with 0-5 age group children for fire management

Conditions: Fever

Summary: the research was conducted in a randomized controlled design to evaluate the effectiveness of the fever management training given to mothers of children aged 0-5.

the research was conducted between january 2023 and april 2023 in the pediatric ward of gebze fatih state hospital. the study included 120 mothers, with 60 in the intervention group and 60 in the control group, who had children aged 0-5 years old admitted to the hospital with a complaint of fever. the data was collected using the 'mother and child information form,' 'parent's fever management scale (pfms),' 'fever management knowledge statements form (fmksf),' and 'follow-up form. the data were analyzed using appropriate statistical methods in the spss (statistical package for social sciences) for windows 26.0 software package.

Eligibility criteria:
inclusion criteria: * mothers with 0-5 age group children in fever * must be literate exclusion criteria: * discharge before 3 days

Keywords: child fever, mother, fever management, education
assessment of safety, tolerability and drug levels of exenatide implant

Conditions: Overweight and Obesity; Type2diabetes

Summary: the purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.


Eligibility criteria:
inclusion criteria: * bmi 27 to 40 kg/m\^2 * estimated glomerular filtration rate (egfr) \>/= 90 ml/min/1.73 m\^2 * hba1c \< 6.0% and fpg \< 6.7 mol/l exclusion criteria: * has a clinically significant medical condition that could potentially affect study participation and/or personal well-being * history of type 1 or type 2 diabetes * history of, or currently has, acute or chronic pancreatitis or has triglyceride concentrations ≥500 mg/dl * has medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia (men ii) or a family history of mtc or men ii * current or past exposure to exenatide